Literature DB >> 5344299

[Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].

W Birkmayer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5344299

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


× No keyword cloud information.
  13 in total

1.  Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.

Authors:  G Campanella; S Algeri; C Cerletti; E Dolfini; A Jori; F Rinaldi
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

2.  Possible mechanism of adverse reaction following levodopa plus benserazide treatment.

Authors:  F S Messiha
Journal:  Br J Pharmacol       Date:  1977-05       Impact factor: 8.739

Review 3.  [Modern treatment of parkinsonism].

Authors:  W Birkmayer; E Neumayer
Journal:  Z Neurol       Date:  1972

4.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

5.  [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].

Authors:  E Schneider; P A Fischer; P Jacobi; H Maxion
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1973-03-19

6.  [The therapeutic effect of L-dopa].

Authors:  P Groneberg; A Struppler
Journal:  Naturwissenschaften       Date:  1972-11

7.  L-deprenyl treatment of on-off phenomena in Parkinson's disease.

Authors:  U K Rinne; T Siirtola; V Sonninen
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

Review 8.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

9.  Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.

Authors:  C D Marsden; P E Barry; J D Parkes; K J Zilkha
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-02       Impact factor: 10.154

10.  Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.

Authors:  Kapil D Sethi; Robert A Hauser; Stuart H Isaacson; Terry McClain
Journal:  Cases J       Date:  2009-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.